The reappointment process had always been an under-the-radar administrative process that didn't attract attention—that is until this year. ...

Oracle shares fell sharply on Thursday, a stark display of investors' concerns about tech companies overspending on artificial-intelligence infrastructure. ...

Canada logged its first trade surplus in eight months in September as exports rebounded and domestic demand showed signs of softening. ...

Robust consumer demand drove higher traffic and spending across stores at Canada's largest dollar-store chain. ...

Lawsuit says Percepta's chief executive built a "copycat†company after leaving Palantir last year ...

The three-year licensing deal will let users generate videos of more than 200 Disney, Marvel, Star Wars and Pixar characters. ...

The U.S. trade deficit decreased in September, declining to the lowest level in five years as trade patterns adjust to the steep new tariffs levied by President Trump. ...

The number of Americans filing new claims for unemployment benefits rose last week but stayed well within the range that has prevailed over the past year. ...

Core Viewpoint - The Organization of the Petroleum Exporting Countries (OPEC) has maintained its oil-demand outlook while preparing to pause output increases in early 2026, but has slightly raised its supply forecast for this year [1] Group 1: Oil Demand Outlook - OPEC has left its oil-demand outlook unchanged, indicating stability in expected consumption levels [1] - The decision reflects confidence in the current market dynamics and demand trends [1] Group 2: Supply Forecast - OPEC has modestly increased its forecast for oil supply for the current year, suggesting a response to market conditions [1] - This adjustment may indicate an anticipation of higher production levels to meet demand [1] Group 3: Output Policy - The organization is preparing to pause output hikes in early 2026, signaling a strategic approach to managing production levels [1] - This pause may be aimed at balancing supply and demand in the oil market [1]

Core Insights - Eli Lilly's experimental weight-loss drug retatrutide has shown significant efficacy in reducing weight and alleviating knee pain in a phase three trial involving patients suffering from obesity and knee osteoarthritis [1] Group 1 - The phase three trial demonstrated that retatrutide resulted in substantial weight loss among participants [1] - Patients reported a reduction in knee pain, indicating potential benefits for those with knee osteoarthritis [1]